1. Home
  2. CARM

as 11-14-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Founded: 2016 Country:
United States
United States
Employees: N/A City: PHILADELPHIA
Market Cap: 41.5M IPO Year: N/A
Target Price: $12.67 AVG Volume (30 days): 183.3K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.55 EPS Growth: N/A
52 Week Low/High: $0.80 - $3.16 Next Earning Date: 11-07-2024
Revenue: $20,268,000 Revenue Growth: 41.13%
Revenue Growth (this year): 50.4% Revenue Growth (next year): -11.20%

CARM Daily Stock ML Predictions

Share on Social Networks: